Kura Oncology (NASDAQ:KURA) Receives “Outperform” Rating from Wedbush

Wedbush reaffirmed their outperform rating on shares of Kura Oncology (NASDAQ:KURA) in a research note published on Tuesday morning,RTT News reports. The brokerage currently has a $36.00 target price on the stock.

KURA has been the topic of several other reports. Cantor Fitzgerald raised Kura Oncology to a “strong-buy” rating in a report on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Kura Oncology in a research report on Thursday, February 27th. JMP Securities restated a “market outperform” rating and issued a $28.00 price target on shares of Kura Oncology in a research report on Thursday, February 6th. Scotiabank lowered their price objective on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 8th. Finally, UBS Group dropped their price objective on shares of Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. Three investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $25.50.

Kura Oncology Trading Down 2.4 %

KURA stock opened at $5.62 on Tuesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. Kura Oncology has a 1-year low of $5.41 and a 1-year high of $23.48. The business has a 50 day simple moving average of $7.55 and a two-hundred day simple moving average of $11.19. The company has a market capitalization of $453.84 million, a price-to-earnings ratio of -2.38 and a beta of 0.83.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.43. The company had revenue of $53.88 million for the quarter, compared to analysts’ expectations of $57.96 million. Research analysts anticipate that Kura Oncology will post -2.44 EPS for the current fiscal year.

Insider Buying and Selling

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares in the company, valued at $694,078.91. This represents a 5.31 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,729 shares of company stock valued at $92,307 in the last ninety days. 5.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of KURA. Rhumbline Advisers boosted its position in shares of Kura Oncology by 5.2% in the 1st quarter. Rhumbline Advisers now owns 105,206 shares of the company’s stock worth $694,000 after purchasing an additional 5,215 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Kura Oncology by 7.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 131,718 shares of the company’s stock worth $1,147,000 after acquiring an additional 9,050 shares in the last quarter. Woodline Partners LP boosted its holdings in Kura Oncology by 20.6% in the fourth quarter. Woodline Partners LP now owns 172,704 shares of the company’s stock worth $1,504,000 after acquiring an additional 29,497 shares in the last quarter. Velan Capital Investment Management LP purchased a new stake in shares of Kura Oncology during the fourth quarter worth about $1,306,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Kura Oncology during the fourth quarter valued at about $799,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.